Steven Feldman to Immunologic Factors
This is a "connection" page, showing publications Steven Feldman has written about Immunologic Factors.
Connection Strength
4.792
-
Glines KR, Stiff KM, Freeze M, Cline A, Strowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Expert Opin Pharmacother. 2019 04; 20(5):621-629.
Score: 0.633
-
Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018 12; 18(6):609-617.
Score: 0.619
-
Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
Score: 0.455
-
Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012 Oct 15; 18(10):1.
Score: 0.411
-
Sumner W, Feldman SR. Conversion to positive tuberculosis test during etanercept treatment of psoriasis. J Drugs Dermatol. 2007 Oct; 6(10):1048.
Score: 0.290
-
Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007 Jul; 143(7):912-5.
Score: 0.285
-
Avasarala JR, O'Donovan CA, Roach SE, Camacho F, Feldman SR. Analysis of NAMCS data for multiple sclerosis, 1998-2004. BMC Med. 2007 Apr 05; 5:6.
Score: 0.280
-
Feldman SR. Intermittent dosing of biologics for psoriasis. J Dermatolog Treat. 2006; 17(1):5.
Score: 0.257
-
Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat. 2006; 17(2):86-9.
Score: 0.257
-
Pearce DJ, Boles A, Greist HM, Feldman SR. Biologic therapy for psoriasis: telephone triage. Dermatol Nurs. 2005 Aug; 17(4):265-70, 295.
Score: 0.250
-
Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. JAMA Dermatol. 2018 08 01; 154(8):903-912.
Score: 0.154
-
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014 Aug; 71(2):327-49.
Score: 0.115
-
Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-a inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014 Feb; 15(1):37-43.
Score: 0.113
-
Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-a inhibitors in psoriasis. J Drugs Dermatol. 2013 Mar; 12(3):e41-5.
Score: 0.106
-
Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012 Dec 01; 13(6):365-74.
Score: 0.104
-
Feldman SR. Message from the guest editor. J Drugs Dermatol. 2012 Aug; 11(8):906.
Score: 0.101
-
Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
Score: 0.087
-
Yentzer BA, Yelverton CB, Simpson GL, Simpson JF, Hwang W, Balkrishnan R, Feldman SR. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009 Apr 15; 15(4):1.
Score: 0.081
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
Score: 0.064
-
Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
Score: 0.061
-
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021 05; 84(5):1254-1268.
Score: 0.045
-
Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012 Aug; 11(8):957-62.
Score: 0.025